Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With PVTT
NCT06622031Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Primary endpoint: Rates of gastrointestinal hemorrhage at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06622031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622031.